CA-SONY-INTERACTIVE
8.9.2021 16:02:09 CEST | Business Wire | Press release
Sony Interactive Entertainment (“SIE”) announced today that SIE has entered into a definitive agreement to acquire Firesprite Limited, the UK-based videogame studio with a history of developing highly-polished showpieces for cutting-edge hardware. With a partnership spanning more than 8 years and a games portfolio highlighting PlayStation’s technological innovations, Firesprite will play a critical role in strengthening SIE’s exclusive games catalog in genres outside of PlayStation Studios’ core offerings.
Founded by industry veterans from SIE’s Studio Liverpool, Firesprite has a strong record of developing showcase games for PlayStation console and peripheral launches. Over the past few years, Firesprite has partnered with SIE to develop games for the PlayStation®4 and PlayStation®VR launch including The Playroom (PS4) and The Playroom VR (PS VR), both of which showcased unique hardware capabilities with highly-quality gameplay.
Originally a PS VR exclusive, with its most recent release, The Persistence , Firesprite pushed the boundaries of how users interact with the PS VR headset by introducing a groundbreaking virtual reality social element that further demonstrated the studio’s technical and creative capabilities. Later adapted for flat screens in 2018, Firesprite recently released The Persistence Enhanced in June 2021 which optimized the game for PlayStation®5 to include DualSense™ wireless controller haptic feedback, adaptive triggers, and raytraced rendering.
“We are delighted to welcome Firesprite into the PlayStation family,” said Jim Ryan, President & CEO, Sony Interactive Entertainment. “We have a rich history of working with the founders of Firesprite and are excited to grow the PlayStation presence in Liverpool. The portfolio of titles Firesprite has developed has continually demonstrated the team’s ability to transcend traditional gameplay experiences and brilliantly showcase the potential of our hardware.”
“Creating quality, state-of-the-art games has always been at the forefront of Firesprite’s work and I’m confident they will push the bar even further as part of PlayStation Studios,” said Hermen Hulst, Head of PlayStation Studios. “Firesprite’s ability to weave best-in-class gameplay with new technology is exceptional and I think fans will be excited about their creative vision for the future.”
“At Firesprite, we’re always striving to bring something new to a game or genre and developing for new technologies is a driving force of our passion,” said Graeme Ankers, Managing Director, Firesprite. “Joining PlayStation Studios will allow us to amplify this passion, working more closely on cutting-edge hardware without any limitations and furthering our studio’s heritage of creativity and technical innovation to offer some truly unique experiences for PlayStation fans.”
Based in Liverpool, UK Firesprite will join the global development operation of PlayStation Studios and will be the 14th studio to join the PlayStation Studios family. The day-to-day operations post-acquisition will continue to be run by Firesprite’s current management team. Terms of this transaction including the acquisition cost are not disclosed due to contractual commitments.
About Sony Interactive Entertainment
Recognized as a global leader in interactive and digital entertainment, Sony Interactive Entertainment (SIE) is responsible for the PlayStation® brand and family of products and services. PlayStation has delivered innovation to the market since the launch of the original PlayStation in Japan in 1994. The PlayStation family of products and services include PlayStation®5, PlayStation®4, PlayStation®VR, PlayStation™Store, PlayStation®Plus, PlayStation™Now, and acclaimed PlayStation software titles from PlayStation Studios. Headquartered in San Mateo, California, SIE is a wholly owned subsidiary of Sony Group Corporation and has global functions in California, London and Tokyo.
About Firesprite
Founded in 2012 by a group of creative and management veterans with years of industry experience, Firesprite is a visionary game development studio based in the heart of Liverpool’s vibrant game development hub with over 200 team members. Creating a number of showcase games for PlayStation console and peripheral launches over the years, Firesprite’s core focus is developing innovative and memorable experiences for players on cutting edge gaming hardware. At Firesprite, the end player experience always comes first and the team is passionate about how to best combine the disciplines of design, art and code to deliver experiences that surprise and delight.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005275/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release
Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical
OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 08:00:00 CEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual
Ant International’s Bettr Partners with Muslim Pro to Introduce Umrah Financing Service in Malaysia10.8.2026 05:49:00 CEST | Press release
Bettr, a leading provider of inclusive and embedded finance and fintech solutions under Ant International, today announced its partnership with Muslim Pro, a popular Islamic lifestyle app serving over 190 million downloads worldwide, to launch an Umrah financing solution in Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260809780047/en/ Ant International's Bettr and Muslim Pro launch an Umrah financing solution in Malaysia to help families better manage their cash flow and spread pilgrimage costs responsibly. The solution is designed for eligible Muslims who have the means to undertake the pilgrimage but prefer to spread its cost over time. This flexibility enables individuals and families to manage their cash flow responsibly, maintain regular savings and preserve sufficient liquidity for emergencies and other financial obligations. The launch marks a significant milestone in Bettr’s Islamic finance initiative and
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom